期刊文献+

化学原料药生产工艺变更研究常见问题分析 被引量:4

Common Problems Analysis of Manufacturing Process Variation Research for Approved Chemical Drug Substances
在线阅读 下载PDF
导出
摘要 目的为规范化学原料药生产工艺变更研究提供参考。方法结合审评工作中的具体案例,对目前原料药生产工艺变更申请中常见的、有一定代表性的问题进行分析。结果与结论原料药生产工艺变更可能引发产品质量特征的变化,需通过对变更前后产品的结构、质量、稳定性等方面进行全面对比研究,来评估变更是否对药品的安全性、有效性和质量可控性产生负面影响。 Objective To provide reference to manufacturing process variation research for approved chemical drug substances.Methods The common problems encountered in the manufacturing process variation research for approved chemical drug substances were analyzed,and the cases in technical review were studied.Results and Conclusion Changes to the manufacturing process may result in alteration of drug quality characteristic.Comparison study on structure,quality and stability prior and after changes should be performed to overall evaluate the impact on safety,efficacy and quality of the final drug product.
作者 于红 马玉楠
出处 《中国药事》 CAS 2011年第1期47-50,共4页 Chinese Pharmaceutical Affairs
关键词 原料药 生产工艺 变更研究 drug substance manufacturing process variation research
  • 相关文献

参考文献13

  • 1国家食品药品监督管理局编.药物研究技术指导原则[M].北京:中国医药科技出版社,2006-2007.
  • 2周海钧.药品注册的国际技术要求:质量部分[M].北京:人民卫生出版社,2006:298-353.
  • 3吕东,黄文龙.FDA有关“质量源于设计”的初步实施情况介绍[J].中国药事,2008,22(12):1131-1133. 被引量:18
  • 4国家食品药品监督管理局.已上市化学药品变更研究的技术指导原则(一)[Z].国食药监注[2008] 242号,2008.
  • 5国家食品药品监督管理局编.药品生产验证指南[M].北京:化学工业出版社,2003:541-592.
  • 6European Pharmacopoeia[S].5版.2004:1297-1299.
  • 7EMEA.Guideline on Stability Testing for Applications for Variations to A Marketing Authorisation[EB/OL].[2005-05-19].http://www.ema.europa.eu/pdfs/human/qwp/057696en.pdf.
  • 8ICH.Impurities in New Drug Substances Q3A(R2)[EB/OL].[2006-10-25].http://www.ich.org/LOB/media/MEDIA422.pdf.
  • 9张宁,于红.化学药品杂质研究思路探析[J].中国新药杂志,2008,17(23):2074-2077. 被引量:21
  • 10余启洪,吴巧玲,贾佳.加兰他敏制备方法研究进展[J].化工生产与技术,2008,15(6):38-41. 被引量:3

二级参考文献30

  • 1王晓燕,黄敏仁,韩正敏.石蒜属植物中加兰他敏的分离提取及其应用[J].南京林业大学学报(自然科学版),2004,28(4):79-83. 被引量:26
  • 2纪庆娥.选择性胆碱酯酶抑制剂──加兰他敏[J].国外医药(合成药.生化药.制剂分册),1994,15(2):93-97. 被引量:9
  • 3Tong C, D'Souza S S, Parker J E, et al. Commentary on AAPS Workshop: dissolution testing for the twenty-first century: linking critical quality attributes and critical process parameters to clinically relevant dissolution [J] . Pharm Res, 2007, 24 (9): 1603.
  • 4Rodrigues L O, Alves T P, Cardoso J P, et al. Improving drug manufacturing with process analytical technology [J] . IDrugs, 2006, 9 (1): 44.
  • 5Henck J O, Byrn S R. Designing a molecular delivery system within a preclinical fimeframe [J] . Drug Discov Today, 2007, 12 (5-6): 189.
  • 6Kozlowski S, Swann P. Current and future issues in the manufacturing and development of monoclonal antibodies [J] . Adv Drug Deliv Rev, 2006, 58 (5-6) : 707.
  • 7Yu L X, Lionberger R A, Raw A S, et al. Applications of process analytical technology to crystallization processes [J] . Adv Drug Deliv Rev, 2004, 56 (3) : 349.
  • 8Lasky F D, Boser R B. Designing in quality through design control: a manufacturer's perspective [J]. Clin Chem, 1997, 43 (5): 866.
  • 9Scott B, Wilcock A. Process analytical technology in the pharmaceutical industry: a toolkit for continuous improvement [J] . PDA J Pharma Sci Technol, 2006, 60 (1) : 17.
  • 10Meij Seika Kaisha. Limited method of extracting vegetable ingredients: GB,1000014[P]. 1965-08-04.

共引文献174

同被引文献15

引证文献4

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部